Clinical trial · Observational
Sentinel Lymph Node Biopsy in Early Breast Cancer: a Real-world Multicenter Cross-sectional Study (CABS001 Study)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Objective: To investigate the current clinical practice of sentinel lymph node biopsy (SLNB) in patients with early stage breast cancer in China. Methods: The data of early breast cancer patients who underwent SLNB in 40 Grade III Level A hospitals in China in 2018 will be collected. Different centers, tracer methods, molecular typing and neoadjuvant chemotherapy will be used as stratification factors to analyze the implementation rate, number of detections, positive rate of SLNB and the follow-up treatment.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Sentinel Lymph Node | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| mapping agent | Diagnostic Test | — | UNRESOLVED |
| neoadjuvant chemotherapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- performed SLNB using a single mapping agent
- interventionNames
- Diagnostic Test: mapping agent
- label
- performed SLNB by combination of blue dye and radiotracer
- interventionNames
- Diagnostic Test: mapping agent
- label
- underwent SLN surgery receiving neoadjuvant chemotherapy
- interventionNames
- Procedure: neoadjuvant chemotherapy
- label
- underwent SLN surgery not receiving neoadjuvant chemotherapy
- interventionNames
- Procedure: neoadjuvant chemotherapy
Primary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * breast cancer confirmed by fine needle aspiration or biopsy * SLNB with or without axillary lymph node dissection * receiving conventional systematic treatment or regional treatment * complete medical record. Exclusion Criteria: * IV stage breast cancer * combined with secondary invasive malignant tumor * diagnosed with other serious disease, including congestive heart failure (NYHA cardiac function grade II, III, IV) or congestive heart failure, unstable angina pectoris, myocardial infarction, high-risk uncontrollable heart rate disorder or other serious cardiovascular diseases within 6 months * difficulty breathing at rest or need oxygen therapy * severe infection * uncontrolled diabetes * serious psychological or mental disorders * poor compliance.
References
Publications (0)
Data not yet available